General Information of Drug (ID: DML3PE4)

Drug Name
Benzimidazole derivative 10 Drug Info
Synonyms PMID26936077-Compound-27
Cross-matching ID
PubChem CID
56848369
TTD Drug ID
DML3PE4

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MEDI0618 DM7GNSY Osteoarthritis pain MG30.31 Phase 1 [2]
Imidazopyridazine derivative 8 DMF7NXJ Inflammation 1A00-CA43.1 Patented [1]
Piperazine urea derivative 4 DM3K7IM Inflammation 1A00-CA43.1 Patented [1]
Piperidine derivative 2 DMHXMB4 Inflammation 1A00-CA43.1 Patented [1]
Benzothiazine-carboxamide compound 2 DMMP2RT Skin inflammation EF20.Y Patented [1]
Peptide analog 71 DMSEKZG N. A. N. A. Patented [1]
Amidine compound 3 DMV0QJ4 Inflammation 1A00-CA43.1 Patented [1]
Benzothiazine-carboxamide compound 4 DMSR918 Skin inflammation EF20.Y Patented [1]
Quinazoline derivative 11 DMAH435 Chronic obstructive pulmonary disease CA22 Patented [1]
PMID26936077-Compound-13 DMXK6LV Gastric ulcer DA60 Patented [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Proteinase activated receptor 2 (PAR2) TTQR74A PAR2_HUMAN Antagonist [1]

References

1 Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
2 Clinical pipeline report, company report or official report of AstraZeneca